Current and emerging treatments for vitiligo

    loading  Checking for direct PDF access through Ovid

Abstract

Clinicians should be aware that vitiligo is not merely a cosmetic disease and that there are safe and effective treatments available for vitiligo. It is important to recognize common and uncommon presentations and those with active disease, as well as their implications for clinical management; these were discussed in the first article in this continuing medical education series. Existing treatments include topical and systemic immunosuppressants, phototherapy, and surgical techniques, which together may serve to halt disease progression, stabilize depigmented lesions, and encourage repigmentation. We discuss how to optimize the currently available treatments and highlight emerging treatments that may improve treatment efficacy in the future.

Learning objectives

After completing this learning activity, participants should be able to choose an optimal approach to management of all patients with vitiligo; list the risks associated with treatment for vitiligo; and discuss emerging treatment options for vitiligo.

Disclosure

Editors

Disclosure

The editors involved with this CME activity and all content validation/peer reviewers of the journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

Authors

The authors involved with this journal-based CME activity other than Dr Harris have reported no relevant financial relationships with commercial interest(s). Dr Harrris has served on advisory boards, as a consultant, or as principle investigator on research agreements with Pfizer, AbbVie, Genzyme/Sanofi, Concert Pharmaceuticals, Stiefel/GSK, Mitsubishi Tanabe Pharma, Novartis, Aclaris Therapeutics, The Expert Institute, Celgene, Biologics MD, and Dermira. Dr Harris' relevant relationship with Pfizer was resolved by nonconflicted reviewers and editors.

Planners

The planners involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s). The editorial and education staff involved with this journal-based CME activity have reported no relevant financial relationships with commercial interest(s).

Related Topics

    loading  Loading Related Articles